Enterprise Value
5.339B
Cash
431.1M
Avg Qtr Burn
-135.2M
Short % of Float
7.27%
Insider Ownership
0.07%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
TransCon PTH Details Adult hypoparathyroidism | NDA Resubmission | |
TransCon hGH Details Adult growth hormone deficiency | Phase 3 Data readout | |
TransCon hGH Details Turner syndrome | Phase 2 Data readout | |
TransCon IL-2 B/y Details Solid tumor/s, Cancer | Phase 2 Data readout | |
TransCon TLR7/8 Agonist +/- pembrolizumab Details Solid tumor/s, Cancer | Phase 2 Data readout | |
TransCon CNP Details Achondroplasia | Phase 2 Data readout | |
TransCon IL-2 B/y + TLR7/8 Details Solid tumor/s, Cancer | Phase 2 Initiation |